Genexine Gets Green Light For Stem Cell Cancer Trial
This article was originally published in PharmAsia News
Executive Summary
South Korean biotech firm Genexine’s R&D pipeline is progressing, with most of its therapies currently in Phase II clinical trials at home and abroad, and a new green light from domestic authorities to conduct a trial with a novel anticancer stem cell and gene therapy.